News Focus
News Focus
icon url

biomaven0

01/11/17 5:44 PM

#207909 RE: xavierprivas #207904

It was two patents denied review - 8,609,646 and 8,466,172

The hepcidin patent likely serves to block AKBA in US as well given any FDA label would talk about use for epo-resistant patients with high hepcidin.

Surviving this review bodes very well for chances of these patents surviving given lower standards of proof and broader claim construction here.